Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of ‘oncogene addiction’, with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may be explained by several molecular and pharmacokinetic features. Therefore, this review integrates preclinical data with clinical evidences of TKIs to guide the optimization of currently available treatments in advanced NSCLC patients.

Bronte, G., Rolfo, C., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., et al. (2014). Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 89(2), 300-313 [10.1016/j.critrevonc.2013.08.003].

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects

BRONTE, Giuseppe;CICERO, Giuseppe;PASSIGLIA, Francesco;CASTIGLIA, Marta;FIORENTINO, Eugenio;RUSSO, Antonio;RIZZO, Sergio
2014

Abstract

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of ‘oncogene addiction’, with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may be explained by several molecular and pharmacokinetic features. Therefore, this review integrates preclinical data with clinical evidences of TKIs to guide the optimization of currently available treatments in advanced NSCLC patients.
Settore MED/06 - Oncologia Medica
Bronte, G., Rolfo, C., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., et al. (2014). Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 89(2), 300-313 [10.1016/j.critrevonc.2013.08.003].
File in questo prodotto:
File Dimensione Formato  
Bronte et al.-Crit Rev Oncol Hematol 2013.pdf

non disponibili

Dimensione 951.58 kB
Formato Adobe PDF
951.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/99172
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 55
social impact